Skip to content
Triangle logo TriangleGet started
← Study library

NCT00041197 · CITED IN SOURCE DOCUMENTS

Imatinib Mesylate in Treating Patients With Primary Gastrointestinal Stromal Tumor That Has Been Completely Removed By Surgery

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2013-07-16

This randomized phase III trial is studying imatinib mesylate to see how well it works compared to placebo in treating patients with primary gastrointestinal stromal tumor that has been completely removed by surgery. Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for patients with primary gastrointestinal stromal tumor that has been completely removed by surgery.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: * Patient must have an ECOG/Zubrod performance status of =\< 2 * Patient must have a histologic diagnosis of primary GIST (without peritoneal or distant metastasis) that expresses Kit protein by immunohistochemistry and have tumor size \>= 3cm in maximum dimension * Patient must have undergone complete gross resection (includes R0 \[negative microscopic margins\] and R1 \[positive microscopic margins\]) of a primary GIST within 70 days prior to registration * Patient must have a chest x-ray completed within 28 days prior to registration; NOTE: Chest CT within 28 days prior to registration can be used in lieu of chest x-ray * Patient must have a post-operative CT scan with IV and PO contrast or MRI with contrast (if allergic to CT contrast) of abdomen and pelvis within 28 days prior to registration * Creatinine =\< 1.5 times the institution ULN * WBC \>= 2,000/mm\^3 * Platelets \>= 100,000/mm\^3 * Total Bilirubin =\< 1.5 times the institution ULN; NOTE: Patients with elevated bilirubin secondary to Gilbert's disease are eligible to participate in the study * AST =\< 2.5 times the institution ULN * ALT =\< 2.5 times the institution ULN * Female of childbearing potential must have negative serum pregnancy test; NOTE: Post-menopausal women must be amenorrheic for at least 12 months to be deemed not of reproductive potential * Patient or the patient's legally acceptable representative must provide a signed and dated written informed consent prior to registration and any study-related procedures * Patient must provide written authorization to allow the use and disclosure of their protected health information; NOTE: This may be obtained in either the study-specific informed consent or in a separate authorization form and must be obtained from the patient prior to study registration (non-US sites are exempt from HIPAA regulations) * If patient is a cancer survivor, ALL of the following criteria apply: * Patient has undergone potentially curative therapy for all prior malignancies * No evidence of any prior malignancies for at least 5 years with no evidence of recurrence (except for effectively treated basal cell or squamous carcinoma of the skin, carcinoma in-situ of the cervix that has been effectively treated by surgery alone, or lobular carcinoma in-situ of the ipsilateral or contralateral breast treated by surgery alone) * Patient is deemed by their treating physician to be at low risk for recurrence from prior malignancies Exclusion Criteria: * Patient has received post-operative chemotherapy * Patient has received post-operative radiation therapy * Patient has received post-operative investigational treatment * Patient has received prior therapy with STI571 * Patient has had an active infection requiring antibiotics within 14 days prior to registration * Patient has objective evidence of residual disease on the postoperative CT scan or MRI of the abdomen or pelvis * Patient, if female and breastfeeding; NOTE: It is not known whether STI571or its metabolites are excreted in human milk; however, in lactating female rats administered 100mg/kg, a dose approximately equal to the maximum clinical dose of 800mg/day based on body surface area, STI571 and /or its metabolites were extensively excreted in milk; it is estimated that approximately 1.5% of a maternal dose is excreted into milk, which is equivalent to a dose to the infant of 30% the maternal dose per unit body weight; women should be advised against breastfeeding while taking STI571 * Patient has New York Heart Association class 3 or 4 cardiac disease * Patient is taking full dose warfarin; NOTE: The use of mini-dose warfarin (1mg orally per day) for prevention of central line-associated deep venous thrombosis is permitted
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive oral imatinib mesylate (Gleevec; STI571) once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence during the year of initial treatment receive imatinib mesylate (Gleevec; STI571) at an increased dose. Patients who develop a recurrence after the year of initial treatment restart imatinib mesylate (Gleevec; STI571) and continue taking the drug at the discretion of the principal investigator.
    intervention Names
    1. Drug: imatinib mesylate
    2. Other: laboratory biomarker analysis
    label
    Arm I (imatinib mesylate)
    type
    EXPERIMENTAL
  2. description
    Patients receive oral placebo once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence at any time discontinue placebo and crossover to arm I. Treatment on arm I continues at the discretion of the principal investigator.
    intervention Names
    1. Other: placebo
    2. Other: laboratory biomarker analysis
    label
    Arm II (placebo)
    type
    PLACEBO_COMPARATOR
interventions
  1. arm Group Labels
    1. Arm I (imatinib mesylate)
    description
    Given orally (PO)
    name
    imatinib mesylate
    other Names
    1. CGP 57148
    2. Gleevec
    3. Glivec
    type
    DRUG
  2. arm Group Labels
    1. Arm II (placebo)
    description
    Given PO
    name
    placebo
    other Names
    1. PLCB
    type
    OTHER
  3. arm Group Labels
    1. Arm I (imatinib mesylate)
    2. Arm II (placebo)
    description
    Correlative studies
    name
    laboratory biomarker analysis
    type
    OTHER
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
DOUBLE
who Masked
  1. PARTICIPANT
  2. INVESTIGATOR
primary Purpose
TREATMENT
Enrollment
count
732
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    An O'Brien-Fleming bound will be used to stop the trial early for superiority of the STI571 arm.
    measure
    Recurrence-free survival (RFS)
    time Frame
    From date of resection to the date of first observation of recurrence, assessed up to 10 years
secondary Outcomes
  1. description
    Safety analysis will consist of routine tabulations, detailed documentation concerning all adverse events, detailed documentation of any unusual events, and any special reports, analyses, or tabulations requested by the DSMC.
    measure
    Safety as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
    time Frame
    Up to 5 years
  2. measure
    Relationship between genetic and phenotypic characteristics of GIST and clinical outcomes
    time Frame
    Up to 10 years
Full study description
brief Summary
This randomized phase III trial is studying imatinib mesylate to see how well it works compared to placebo in treating patients with primary gastrointestinal stromal tumor that has been completely removed by surgery. Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for patients with primary gastrointestinal stromal tumor that has been completely removed by surgery.
detailed Description
PRIMARY OBJECTIVES: I. To determine whether patients with resected primary gastrointestinal stromal tumor (GIST) who are randomized to the STI571 (imatinib mesylate) Arm have longer recurrence-free survival as compared to the patients randomized to the placebo Arm. SECONDARY OBJECTIVES: I. To ascertain whether patients with resected primary GIST who are randomized to the STI571 Arm have longer survival as compared to the patients randomized to the placebo Arm. II. To obtain from patients with GIST: tumor tissue (before therapy with STI571 and if the patient develops recurrence), blood specimens (before therapy with STI571), and serum specimens (before therapy with STI571, after completing therapy with STI571, and if the patient develops recurrence) for scientific correlative analyses. III. To assess the safety/efficacy of oral STI571 therapy in the adjuvant setting. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive oral imatinib mesylate (Gleevec; STI571) once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence during the year of initial treatment receive imatinib mesylate (Gleevec; STI571) at an increased dose. Patients who develop a recurrence after the year of initial treatment restart imatinib mesylate (Gleevec; STI571) and continue taking the drug at the discretion of the principal investigator. ARM II: Patients receive oral placebo once daily. Treatment continues for 1 year in the absence of unacceptable toxicity. Patients who develop a recurrence at any time discontinue placebo and crossover to arm I. Treatment on arm I continues at the discretion of the principal investigator. Patients are followed every 3 months for 2 years, then every 6 months for 10 years.
Source references
references
  1. citation
    Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014 May 20;32(15):1563-70. doi: 10.1200/JCO.2013.51.2046. Epub 2014 Mar 17.
    pmid
    24638003
    type
    DERIVED
  2. citation
    Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K; American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Mar 28;373(9669):1097-104. doi: 10.1016/S0140-6736(09)60500-6. Epub 2009 Mar 18.
    pmid
    19303137
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-59196a61e47bce7f36d3
      requested nct id
      NCT00041197
      primary nct id
      NCT00041197
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      dc65ea27069b2a555937675046eef3875af3e654cbd5b12dc4e6759d872d85c7
      payload sha256
      e6c22d0d5b1511f10870eb305ffee11bd917270e3b0529192e3791ba04bfb24d
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-59196a61e47bce7f36d3
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00041197
      occurrences
      1. context exact
        4" tabindex="-1">Evidence (phase III studies of postoperative imatinib):</p> <div class="pdq-content-list"><ol id="_405"><li><a href="/clinicaltrials/NCT00041197">ACOSOG Z9001</a> (NCT00041197) was a phase III, double-blind, placebo-controlled trial of 713 patients with fully resected <em class="gene-name">KIT</em>-vari
        end
        92028
        exact text
        NCT00041197
        start
        92017
      2. context exact
        e III studies of postoperative imatinib):</p> <div class="pdq-content-list"><ol id="_405"><li><a href="/clinicaltrials/NCT00041197">ACOSOG Z9001</a> (NCT00041197) was a phase III, double-blind, placebo-controlled trial of 713 patients with fully resected <em class="gene-name">KIT</em>-variant GISTs measuring at least 3
        end
        92059
        exact text
        NCT00041197
        start
        92048
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/56f3a793bc98f402b9.html
      source file sha256
      dc65ea27069b2a555937675046eef3875af3e654cbd5b12dc4e6759d872d85c7
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:22:19.967119+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      ad589beab368bd0fb781a6e8f9ce2015eb8c80c2e12bd848c86e9cc1d3cce153
      source title
      Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: December 13, 2024
        datetime
        2024-12-13T12:00:00Z
        display
        December 13, 2024

    Preserved source evidence · Not medical advice